Literature DB >> 22108722

Myocyte changes in heart failure.

Olga V Savinova1, A Martin Gerdes.   

Abstract

Structural remodeling is a major feature of heart failure and typically precedes the development of symptomatic disease. Structural remodeling of the heart reflects changes in myocyte morphology. Disproportional myocyte growth is observed in pathologic concentric hypertrophy (myocyte thickening) and in eccentric dilated hypertrophy (myocyte lengthening). Alterations in myocyte shape lead to changes in chamber geometry and wall stress. Human and animal studies indicate that changes in myocyte morphology are reversible. Normalization or reversal of maladaptive cardiomyocyte remodeling should be a therapeutic aim that can prevent deterioration or improve cardiac function in heart failure. 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22108722     DOI: 10.1016/j.hfc.2011.08.004

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  8 in total

1.  Matrix elasticity regulates the optimal cardiac myocyte shape for contractility.

Authors:  Megan L McCain; Hongyan Yuan; Francesco S Pasqualini; Patrick H Campbell; Kevin Kit Parker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-28       Impact factor: 4.733

2.  Organ-level right ventricular dysfunction with preserved Frank-Starling mechanism in a mouse model of pulmonary arterial hypertension.

Authors:  Zhijie Wang; Jitandrakumar R Patel; David A Schreier; Timothy A Hacker; Richard L Moss; Naomi C Chesler
Journal:  J Appl Physiol (1985)       Date:  2018-01-25

3.  Predicting the Time Course of Ventricular Dilation and Thickening Using a Rapid Compartmental Model.

Authors:  Colleen M Witzenburg; Jeffrey W Holmes
Journal:  J Cardiovasc Transl Res       Date:  2018-03-17       Impact factor: 4.132

4.  Atrophic cardiomyocyte signaling in hypertensive heart disease.

Authors:  German Kamalov; Wenyuan Zhao; Tieqiang Zhao; Yao Sun; Robert A Ahokas; Tony N Marion; Fahed Al Darazi; Ivan C Gerling; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2013-12       Impact factor: 3.105

Review 5.  Multiphysics and multiscale modelling, data-model fusion and integration of organ physiology in the clinic: ventricular cardiac mechanics.

Authors:  Radomir Chabiniok; Vicky Y Wang; Myrianthi Hadjicharalambous; Liya Asner; Jack Lee; Maxime Sermesant; Ellen Kuhl; Alistair A Young; Philippe Moireau; Martyn P Nash; Dominique Chapelle; David A Nordsletten
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

6.  Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor.

Authors:  Wei-Wei Zhang; Feng Bai; Jin Wang; Rong-Hua Zheng; Li-Wang Yang; Erskine A James; Zhi-Qing Zhao
Journal:  Drug Des Devel Ther       Date:  2017-10-16       Impact factor: 4.162

7.  Interval and continuous exercise enhances aerobic capacity and hemodynamic function in CHF rats.

Authors:  Ramiro B Nunes; Jadson P Alves; Luíza P Kessler; André Z Dornelles; Giuseppe P Stefani; Pedro D Lago
Journal:  Braz J Phys Ther       Date:  2015-09-01       Impact factor: 3.377

Review 8.  Engineering the Cellular Microenvironment of Post-infarct Myocardium on a Chip.

Authors:  Natalie N Khalil; Megan L McCain
Journal:  Front Cardiovasc Med       Date:  2021-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.